Literature DB >> 28441861

Anionic Polymer and Quantum Dot Excipients to Facilitate siRNA Release and Self-Reporting of Disassembly in Stimuli-Responsive Nanocarrier Formulations.

Chad T Greco1, Jason C Andrechak1, Thomas H Epps1, Millicent O Sullivan1.   

Abstract

The incorporation of anionic excipients into polyplexes is a promising strategy for modulating siRNA binpan>dinpan>g versus release and inpan>tegratinpan>g diagnpan>ostic capabilities; however, specific designpan> criteria and structure-funpan>ction relationships are needed to facilitate the developmenpan>t of nanocarrier-based theranostics. Hereinpan>, we inpan>corporated poly(acrylic acid) (PAA) and quantum dot (QD) excipients into photolabile siRNA polyplexes to increase gene silencing efficiencies by up to 100% and enable self-reporting of nanocarrier disassembly. Our systematic approach identified the functional relationships between gene silencing and key parameters such as excipient loading fractions and molecular weights that facilitated the establishment of design rules for optimization of nanocarrier efficacy. For example, we found that PAA molecular weights ∼10-20× greater than that of the coencapsulated siRNA exhibited the most efficient release and silencing. Furthermore, siRNA release assays and RNAi modeling allowed us to generate a PAA "heat map" that predicted gene silencing a priori as a function of PAA molecular weight and loading fraction. QDs further promoted selective siRNA release and provided visual as well as Förster resonance energy transfer (FRET)-based monitoring of the dynamic changes in nanostructure in situ. Moreover, even with the addition of anionic components, our formulations exhibited substantially improved stability and shelf life relative to typical formulations, with complete stability after a week of storage and full activity in the presence of serum. Taken together, this study enabled synergistic improvements in siRNA release and diagnostic capabilities, along with the development of mechanistic insights that are critical for advancing the translation of nucleic acid theranostics into the clinic.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28441861      PMCID: PMC5672795          DOI: 10.1021/acs.biomac.7b00265

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  55 in total

1.  Advancing polymeric delivery systems amidst a nucleic acid therapy renaissance.

Authors:  Paul A Burke; Suzie H Pun; Theresa M Reineke
Journal:  ACS Macro Lett       Date:  2013-10-15       Impact factor: 6.903

2.  Evaluating the intracellular stability and unpacking of DNA nanocomplexes by quantum dots-FRET.

Authors:  Yi-Ping Ho; Hunter H Chen; Kam W Leong; Tza-Huei Wang
Journal:  J Control Release       Date:  2006-09-22       Impact factor: 9.776

3.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

Review 4.  Stimuli-responsive polymers: biomedical applications and challenges for clinical translation.

Authors:  Allan S Hoffman
Journal:  Adv Drug Deliv Rev       Date:  2012-12-12       Impact factor: 15.470

5.  siRNA-lipid nanoparticles with long-term storage stability facilitate potent gene-silencing in vivo.

Authors:  Y Suzuki; K Hyodo; Y Tanaka; H Ishihara
Journal:  J Control Release       Date:  2015-10-19       Impact factor: 9.776

6.  Efficient tuning of siRNA dose response by combining mixed polymer nanocarriers with simple kinetic modeling.

Authors:  Chad T Greco; Victoria G Muir; Thomas H Epps; Millicent O Sullivan
Journal:  Acta Biomater       Date:  2017-01-04       Impact factor: 8.947

7.  Spatial Control of Gene Expression by Nanocarriers Using Heparin Masking and Ultrasound-Targeted Microbubble Destruction.

Authors:  Beata Chertok; Robert Langer; Daniel G Anderson
Journal:  ACS Nano       Date:  2016-07-29       Impact factor: 15.881

8.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Authors:  Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

9.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Authors:  Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.